恆瑞醫藥(600276.SH)擬6億-12億元回購股份 回購價格上限60.22元/股
格隆匯3月13日丨恆瑞醫藥(600276.SH)公佈,2022年3月13日,公司召開第八屆董事會第十六次會議,審議通過《關於回購公司股份方案的議案》,獨立董事已就該事項發表了同意意見。根據《公司章程》有關規定,公司本次回購方案無須提交股東大會審議。
基於對公司未來發展前景的信心和基本面的判斷,為維護公司和廣大投資者的利益,完善公司員工長效激勵機制,充分調動員工的積極性,公司計劃以自有資金回購公司股份。本次回購的股份將用於員工持股計劃或者股權激勵。
公司擬用於回購的資金總額不低於6億元,不超過人民幣12億元。如以回購資金總額上限人民幣12億元、回購價格上限60.22元/股測算,預計回購股份數量約為1992.69萬股,約佔公司目前總股本的0.31%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.